<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795361</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-609-5005</org_study_id>
    <nct_id>NCT05795361</nct_id>
  </id_info>
  <brief_title>Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome</brief_title>
  <official_title>Post-trial Access Program: Idursulfase-IT (HGT-2310) in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      This post-trial access program is to allow continued access for people who participated and&#xD;
      are benefitting from treatment on the HGT-HIT-046 (NCT01506141) or SHP609-302 (NCT02412787)&#xD;
      studies, which will be closed down. Idursulfase-IT also known as TAK-609, is a medicine to&#xD;
      help treat Hunter Syndrome and issues with remembering, learning new things, and&#xD;
      concentrating, also called cognitive impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Hunter Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idursulfase-IT</intervention_name>
    <description>Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 [NCT01506141] or SHP609-302 [NCT02412787] study [10mg or 30mg] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.</description>
    <other_name>HGT-2310</other_name>
    <other_name>TAK-609</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants will have completed the treatment period of the HGT-HIT-046 (NCT01506141)&#xD;
             or SHP609-302 (NCT02412787) study prior to the first dose on this program.&#xD;
&#xD;
          2. Participant and/or a parent(s)/legal guardian is informed of the nature of this&#xD;
             compassionate post-trial access program and can provide written informed consent for&#xD;
             themselves or the child to participate (with assent from the child when appropriate&#xD;
             prior to treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has a condition that in the opinion of the treating physician may&#xD;
             compromise their safety.&#xD;
&#xD;
          2. Participant has a known hypersensitivity to idursulfase-IT or its components.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/1a50b2ee12ee4e80?idFilter=%5B%22TAK-609-5005%22%5D</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 6, 2023</last_update_submitted>
  <last_update_submitted_qc>April 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

